Hoth Therapeutics (HOTH) to Release Quarterly Earnings on Wednesday

Hoth Therapeutics (NASDAQ:HOTH) is projected to announce its results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.1031) per share for the quarter.

Hoth Therapeutics Stock Performance

Shares of HOTH stock opened at $1.05 on Monday. The stock has a fifty day simple moving average of $1.01 and a two-hundred day simple moving average of $1.25. The firm has a market capitalization of $16.29 million, a PE ratio of -0.99 and a beta of 0.56. Hoth Therapeutics has a 52-week low of $0.66 and a 52-week high of $2.12.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Lido Advisors LLC bought a new stake in Hoth Therapeutics in the third quarter worth $32,000. Kestra Private Wealth Services LLC purchased a new position in shares of Hoth Therapeutics in the 3rd quarter worth $51,000. Virtu Financial LLC bought a new stake in shares of Hoth Therapeutics in the 3rd quarter worth about $184,000. Geode Capital Management LLC raised its position in shares of Hoth Therapeutics by 8.0% during the 2nd quarter. Geode Capital Management LLC now owns 122,575 shares of the company’s stock valued at $143,000 after buying an additional 9,071 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new stake in shares of Hoth Therapeutics during the 3rd quarter valued at about $232,000. 7.08% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms recently issued reports on HOTH. Weiss Ratings reiterated a “sell (e+)” rating on shares of Hoth Therapeutics in a research report on Monday, December 22nd. D. Boral Capital restated a “buy” rating and issued a $5.00 price target on shares of Hoth Therapeutics in a research note on Thursday, December 4th. Finally, Wall Street Zen cut shares of Hoth Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $5.00.

About Hoth Therapeutics

Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.